Vnitr Lek 2023, 69(7):469-472 | DOI: 10.36290/vnl.2023.091
What's new in endocrinology?
- 3. interní klinika - klinika endokrinologie a metabolismu, 1. LF UK a Všeobecná fakultní nemocnice v Praze
Present article informs about selected recent developments in clinical endocrinology. Neuroendocrinology section is devoted mainly to developments in medical therapy of pituitary disorders, namely Cushing's syndrome and acromegaly. Update of guidelines on management of Cushing' syndrome is also mentioned. Thyroid section informs about ETA consensus on indication for post-surgical radioiodine therapy in differentiated thyroid cancer and also about new therapy for thyroid-associated ophthalmopathy-monoclonal antibody against IGF-1R teprotumumab. Large section reviews major changes covered in recent clinical practice guidelines on the management of adrenal incidentalomas in comparison with previous ones from 2016. Finally, new study on cardiovascular safety of testosterone replacement therapy in hypogonadal men TRAVERSE is discussed.
Keywords: neuroendocrinology, thyroid cancer, teprotumumab, adrenal incidentaloma, testosterone.
Accepted: October 19, 2023; Published: October 26, 2023 Show citation
References
- MacFarlane J, Bashari WA, Senanayake R, et al. Advances in the Imaging of Pituitary Tumors. Endocrinol Metab Clin North Am. 2020;49(3):357-373.
Go to original source... 
Go to PubMed... - Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9(12):847-875. Go to original source... Go to PubMed...
- Fleseriu M, Biller BMK, Bertherat J, et al. Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2). Pituitary 2022;26(6):959-970. Go to original source... Go to PubMed...
- Fleseriu M, Auchus R, Greenman Y, et al. Levoketoconazole treatment in endogenous Cushing's syndrome: extended evaluation of clinical, biochemical, and radiological outcomes. Eur J Endocrinol. 2022;187(6):859-871. Go to original source... Go to PubMed...
- Zhao J, Fu H, Yu J, et al. Prospect of acromegaly therapy: molecular mechanisms of clinical drugs octreotide and paltusotine. Nat Commun. 2023;14:962. Go to original source... Go to PubMed...
- Samson SL, Nachtigall LB, Fleseriu M, et al. Durable biochemical response and safety with oral octreotide capsules in acromegaly. Eur J Endocrinol. 2022;187(6):733-741. Go to original source... Go to PubMed...
- Pacini F, Fuhrer D, Elisei R, et al. 2022 ETA Consensus statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur Thyroid J. 2022;11(1):e210046. Go to original source... Go to PubMed...
- Slentz DH, Nelson CC, Smith TJ. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy. Expert Opin Investig Drugs. 2020;29(7):645-649. Go to original source... Go to PubMed...
- Stan MN, Krieger CC. The adverse effects profile of teprotumumab. J Clin Endocrinol Metab. 2023; E-pub Ahead of print. Go to original source... Go to PubMed...
- Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023; E-pub ahead of print. Go to original source... Go to PubMed...
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Eng J Med. 2023; E-pub ahead of print. Go to original source... Go to PubMed...